Overview

Therapeutics in Active Prostate Cancer Surveillance

Status:
Completed
Trial end date:
2019-07-25
Target enrollment:
Participant gender:
Summary
Testing if short-term use of apalutamide can reduce image defined tumour volumes in men with detectable lesion on multi-parametric Magnetic Resonance Imaging (mpMRI) and being managed by Active Surveillance. The trial will also evaluate the tolerability and side effect profile of men on AS using short term apalutamide and patient acceptability as a therapeutic strategy, as well as determining feasibility of a larger prospective randomised trial of apalutamide.
Phase:
Phase 2
Details
Lead Sponsor:
CCTU- Cancer Theme
Collaborator:
Janssen-Cilag Ltd.